According to the latest research of Penn State College of Medicine and the National Institute of Environmental Health Sciences, statins may not provide protection against the Parkinson’s disease. Previously, statins are considered beneficial against the Parkinson’s.
There’s so many advantages and benefits being attributed to statins but one thing it does not provide protection against Parkinson’s disease. The previous study about its ability to treat Parkinson’s disease has not been conclusive.
There are about a million individuals who suffers from Parkinson’s disease worldwide.
A lot about the disease is still unknown to scientists. One thing for sure however is that damaged neurons produce dopamine which leads to uncontrolled movements on the part of the patients.
Vice chair for research and professor of neurology at Penn State College of Medicine, Xuemei Huang, said “, Former studies showed an association between high cholesterol levels in blood with reduced levels of Parkinson’s.”
The data from the study however needs more back up from other studies similar to it.
Some studies have concluded that statin can reduce the incidence of Parkinson’s disease if used as the choice drug of treatment. It lowers low density cholesterol level (LDL) which is considered the bad cholesterol as opposed to HDL or high density cholesterol level, which is considered the good cholesterol. It is still unclear whether use of statins can reduce the Parkinson’s incidence, and this study was determined to find the link.
The data was collected from the Atherosclerosis Risk Communities study; Huang and team looked at the cholesterol levels, Parkinson’s symptoms and medication history.
The result of the study showed that there is a connection between high presence of cholesterol and LDL and how they affect Parkinson’s disease.
Statin doesn’t only reduce Parkinson risk but instead it does the opposite.
Huang explained why some studies found statins to be effectual by suggesting, “One possibility, is that statin use can be a marker of people who have high cholesterol, which itself may be associated with lower [Parkinson’s] risk. This could explain why some studies have found an association between use of these medications and low incidence of [Parkinson’s]. Most importantly, this purported benefit may not be seen over time.”
The details of this study were published in the journal Movement Disorders.